Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metal Panel Allergens Dose Response Study
NCT02615249Phase 2Completed
- Sponsor
- Allerderm Laboratories, Inc.
- Start
- Dec 2016
- Primary completion
- Jul 2019
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of copper sulfate, manganese, molybdenum, Vanadium and zinc aluminium ointment in allergic contact dermatitis (ACD), sponsored by Allerderm Laboratories, Inc. Primary endpoint: Number of Participants With Patch Test Responses at 21 days. Started Dec 2016; status: completed.
02
Drugs
copper sulfatemanganesemolybdenumVanadiumzinc aluminium ointment
03
Conditions
allergic contact dermatitis (ACD)
Beyond the preview
Go deeper on NCT02615249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02615249.